References
- Acemoglu , D. and Linn , J. 2004 . Market size in innovation: theory and evidence from the pharmaceutical industry . Quarterly journal of economics , 119 : 1049 – 1090 .
- Anderson , G. and Hussey , P. 2000 . Population aging: a comparison among industrialized countries . Health affairs , 19 : 191 – 203 .
- Bottazzi , G. , Dosia , G. , Lippi , M. , Pammolli , F. and Riccaboni , M. 2001 . Innovation and corporate growth in the evolution of the drug industry . International journal of industrial organization , 19 : 1161 – 1187 .
- Filatotchev , I. and Piesse , J. 2009 . R&D, internationalization and growth of newly listed firms: European evidence . Journal of international business studies , 40 : 1260 – 1276 .
- Grabowski , H. and Vernon , J. 2000 . The determinants in pharmaceutical research and development expenditures . Journal of evolutionary economics , 10 : 201 – 215 .
- Griliches , Z. 1981 . Market value, R&D, and patents . Economic letters , 7 : 183 – 187 .
- Hall , B. 1980s . The stock market valuation of R&D investment during the 1980s . American economic review , 83 : 259 – 264 .
- Hall , B. 2002 . The financing of research and development . Oxford review of economic policy , 18 : 35 – 51 .
- Hoshi , T. , Kashyap , A. and Scharfstein , D. 1991 . Corporate structure, liquidity and investment: evidence from Japanese panel data . Quarterly journal of economics , 100 : 33 – 60 .
- Hoshi , T. and Kashyap , A. 2001 . Corporate financing and governance in Japan: the road to the future , Cambridge, MA : MIT Press .
- Hubbard , R. 1998 . Capital market imperfections and investment . Journal of economic literature , 26 : 193 – 225 .
- Ikegami , N. and Campbell , J. 2004 . Japan's health care system: containing costs and attempting reform . Health affairs , 23 : 26 – 36 .
- Jacobzone , S. 2000 . Coping with ageing: international challenges . Health affairs , 19 : 213 – 225 .
- John , K. , Litov , L. and Yeung , B. 2008 . Corporate governance and risk–taking . Journal of finance , 63 : 1679 – 1728 .
- Lev, B., Radhakrishnan, S., and Ciftci, M., 2005. The stock market valuation of R&D leaders. Working paper, New York University
- Long , W. and Ravenscraft , D. 1993 . LBOs, debt and R&D intensity . Strategic management journal , 14 : 119 – 135 .
- Mahlich , J. and Roediger–Schluga , T. 2006 . The determinants of pharmaceutical R&D expenditures: evidence from Japan . Review of industrial organization , 28 : 145 – 164 .
- Megna , P. and Klock , M. 1993 . The impact of intangible capital on Tobin's Q in the semiconductor industry . American economic review , 83 : 265 – 269 .
- Müller , E. and Zimmermann , V. 2009 . The importance of equity finance for R&D activity . Small business economics , 33 : 303 – 318 .
- Myers , S. 1977 . Determinants of corporate borrowing . Journal of financial economics , 5 : 147 – 175 .
- Nguyen , P. , Nivoix , S. and Noma , M. 2010 . The valuation of R&D expenditures in Japan . Accounting and finance , 50 ( 4 ) : 899 – 920 .
- Oliver , A. , Ikegami , N. and Ikeda , S. 1997 . Japan's ageing population: implications for healthcare . Pharmaco economics , 11 : 306 – 318 .
- Sapienza , H. , Autio , E. , George , G. and Zahra , S. 2006 . A capabilities perspective on the effects of early internationalization on firm survival and growth . Academy of management review , 31 : 914 – 933 .
- Scherer , F. , Harhoff , D. and Kukies , J. 2000 . Uncertainty and the size distribution of rewards from innovation . Journal of evolutionary economics , 10 : 175 – 200 .
- Schwartz , E. 2004 . Patents and R&D as real options . Economic notes , 33 : 23 – 54 .